Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
Exploring the companies and themes that make up this emerging and exciting new sector
Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America's First Integrative Mental Health Clinic Network
Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating "distress" among frontline healthcare practitioners.
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.
Novamind Unveils New Logo and Invests in Unified Brand
Novamind announces unified branding of all subsidiaries and brands, and includes a new corporate logo.
COMPASS Pathways granted fifth US patent for crystalline psilocybin
The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
Cybin Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities
The program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States.
Industry Buzz Growing Rapidly Around MINDCURE’s iSTRYM
Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
Psychedelics-Assisted Therapy: Effective, Economical AND Imperative
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Compass study result validates industry's hope to find alternative treatments for mental health
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues.
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.